The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.
The trial, which received positive feedback from the FDA, will enroll patients who have a biomarker that may increase their chances of responding to the drug.
The company is developing T-cell receptor therapies, several of which have entered early-phase trials, that target unique peptides identified through mass spectrometry.
The company announced the FDA has cleared its IND for ATA2271, allowing it to start a Phase I study of the autologous CAR T-cell therapy in advanced mesothelioma.
The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.
In the dose expansion portion of the trial, CFI-402257 will be evaluated in three arms, including estrogen receptor-positive, HER2-negative breast cancer, TNBC, and solid tumor patients.
The first-in-human trial will evaluate the safety, tolerability, and anti-tumor activity of SBT6050, a TLR8 agonist conjugated to a HER2-directed monoclonal antibody.
The company is hoping that ACE1702 will validate its antibody cell conjugation technology and show that its proprietary NK cells are more effective than current cell-based therapies.
The FDA has accepted an investigational new drug application for the long-acting human interleukin-7, NT-17, combined with standard-of-care CD19 CAR T-cell therapy.
